CUMC's Laboratory of Personalized Genomic Medicine granted approval for Columbia Combined Cancer Panel

The Laboratory of Personalized Genomic Medicine at Columbia University Medical Center (CUMC) has been granted full approval by the New York State Department of Health for the Columbia Combined Cancer Panel, (CCCP). This panel queries 467 cancer-related genes and was designed in collaboration with Columbia University Medical Center oncologists. The CCCP is one of the few approved clinical oncology panels of this type available in the New York area. This Columbia University laboratory provides services as part of ColumbiaDoctors, the faculty practice of CUMC.

A sequencing-only test, the CCCP uses the Illumina HiSeq2500 platform, and is conducted within Columbia University's Personalized Genomic Medicine (PGM) CLIA-certified, CAP-accredited clinical genomics laboratory. Samples accepted for testing include paraffin-embedded tissue, fresh and frozen tissue--with or without microdissection to enrich for tumor--blood, and bone marrow.

The cancer panel joins the TruSeq Targeted Cancer Panel of New York State-approved oncology tests available within CUMC's Laboratory of Personalized Genomic Medicine (PGM). PGM currently offers more than 14 clinical diagnostic tests in oncology, including a 46 gene targeted panel, targeted testing for KRAS, EGFR, BRAF, JAK2 V617F, clonality testing, BCR-ABL quantitative testing by RT-PCR, MGMT methylation analysis, and EGFRviii RNA expression. In addition, cancer whole exome and transcriptome sequencing is available by waivers on a case-by-case basis, while awaiting final state approval. A comprehensive array of fluorescent and chromogenic in-situ hybridization assays is also available through CUMC's Division of Anatomic Pathology and the Cancer Cytogenetics Laboratory.

Source: Columbia University Medical Center